← Back to Search

Pharmacogenomics Test

Pharmacogenomics Testing for Overmedication

N/A

Waitlist Available

Led By Ryley Uber, Pharm.D.

Research Sponsored by Geisinger Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Active prescriptions for 5 or more medications

Be older than 65 years old

Must not have

History of allogenic hematopoetic stem cell transplantation

History of liver transplantation

Timeline

Screening 3 weeks

Treatment Varies

Follow Up date of test results reported to end of study, up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial tests if a DNA test can help tailor meds to an aging population, improving care and reducing costs.

Who is the study for?

This trial is for older adults who are patients at Geisinger 65 Forward clinics and take five or more medications. It's not open to those who've had liver transplants, stem cell transplants, or were part of the eMERGE pharmacogenomics study.

What is being tested?

The trial is testing a multigene pharmacogenomics test that examines DNA to guide medication choices and dosages for geriatric patients, aiming to improve healthcare outcomes and reduce costs.

What are the potential side effects?

Since this intervention involves genetic testing without direct medication or treatment changes, there are no direct side effects; however, results may influence future medication adjustments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am currently taking 5 or more medications.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have had a stem cell transplant from a donor.

Select...

I have had a liver transplant.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ date of test results reported to end of study, up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~date of test results reported to end of study, up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and date of test results reported to end of study, up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of pharmacogenomic results returned in patients' health records

Secondary study objectives

Composite of changes to medication therapy

Costs of clinical care

Medical costs of care

+3 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Pharmacogenomics TestingExperimental Treatment1 Intervention

Patients in the experimental arm will be ordered a multigene pharmacogenomics test. This DNA test requires a blood draw, with the results expected to be reported in the medical record approximately 7 to 14 calendar days after the blood draw. These results will be made available to Geisinger healthcare professionals that have a treatment relationship with study participants.

Group II: Standard of CareActive Control1 Intervention

A multigene pharmacogenomics test will not be ordered for patients in this study arm, as is the standard of care.

0 / 3Eligibility criteria met